Therapeutic antibodies for autoimmunity and inflammation

被引：667

作者：

Chan, Andrew C. ^{[1
]}

Carter, Paul J. ^{[2
]}

机构：

[1] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA

[2] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA

来源：

NATURE REVIEWS IMMUNOLOGY | 2010年 / 10卷 / 05期

关键词：

INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; CHRONIC IDIOPATHIC URTICARIA; ANTITUMOR NECROSIS FACTOR; NEONATAL FC-RECEPTOR; B-CELL DEPLETION; COLLAGEN-INDUCED ARTHRITIS; GROWTH-FACTOR RECEPTOR; EPSILON-RI EXPRESSION; HUMAN IGG1; RHEUMATOID-ARTHRITIS;

D O I：

10.1038/nri2761

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The development of therapeutic antibodies has evolved over the past decade into a mainstay of therapeutic options for patients with autoimmune and inflammatory diseases. Substantial advances in understanding the biology of human diseases have been made and tremendous benefit to patients has been gained with the first generation of therapeutic antibodies. The lessons learnt from these antibodies have provided the foundation for the discovery and development of future therapeutic antibodies. Here we review how key insights obtained from the development of therapeutic antibodies complemented by newer antibody engineering technologies are delivering a second generation of therapeutic antibodies with promise for greater clinical efficacy and safety.

引用

页码：301 / 316

页数：16

共 164 条

[1]

ALEGRE ML, 1994, TRANSPLANTATION, V57, P1537

[2] Humanization of antibodies [J].

Almagro, Juan C. ;

Fransson, Johan .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 :1619-1633

[3] The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].

Anolik, JH ;

Campbell, D ;

Felgar, RE ;

Young, F ;

Sanz, I ;

Rosenblatt, J ;

Looney, RJ .

ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459

[4] IL-1, IL-18, and IL-33 families of cytokines [J].

Arend, William P. ;

Palmer, Gaby ;

Gabay, Cem .

IMMUNOLOGICAL REVIEWS, 2008, 223 :20-38

[5] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].

Baert, F ;

Noman, M ;

Vermeire, S ;

Van Assche, G ;

D'Haens, G ;

Carbonez, A ;

Rutgeerts, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608

[6] Bispecific T-Cell Engaging Antibodies for Cancer Therapy [J].

Baeuerle, Patrick A. ;

Reinhardt, Carsten .

CANCER RESEARCH, 2009, 69 (12) :4941-4944

[7] Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].

Bargou, Ralf ;

Leo, Eugen ;

Zugmaier, Gerhard ;

Klinger, Matthias ;

Goebeler, Mariele ;

Knop, Stefan ;

Noppeney, Richard ;

Viardot, Andreas ;

Hess, Georg ;

Schuler, Martin ;

Einsele, Hermann ;

Brandl, Christian ;

Wolf, Andreas ;

Kirchinger, Petra ;

Klappers, Petra ;

Schmidt, Margit ;

Riethmueller, Gert ;

Reinhardt, Carsten ;

Baeuerle, Patrick A. ;

Kufer, Peter .

SCIENCE, 2008, 321 (5891) :974-977

[8] Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis [J].

Bartelds, Geertje M. ;

Wijbrandts, Carla A. ;

Nurmohamed, Michael T. ;

Stapel, Steven ;

Lems, Willem F. ;

Aarden, Lucien ;

Dijkmans, Ben A. C. ;

Tak, Paul Peter ;

Wolbink, Gerrit Jan .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (07) :921-926

[9] Omalizumab-induced reductions in mast cell FcεRI expression and function [J].

Beck, LA ;

Marcotte, GV ;

MacGlashan, D ;

Togias, A ;

Saini, S .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (03) :527-530

[10] Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation [J].

Beers, Stephen A. ;

Chan, Claude H. T. ;

James, Sonya ;

French, Ruth R. ;

Attfield, Kathrine E. ;

Brennan, Claire M. ;

Ahuja, Anupama ;

Shlomchik, Mark J. ;

Cragg, Mark S. ;

Glennie, Martin J. .

BLOOD, 2008, 112 (10) :4170-4177

← 1 2 3 4 5 6 7 8 9 10 →